Medison and Alnylam Strengthen Partnership to Bring Innovative RNAi Solutions to LATAM and APAC

Medison Pharma, a global pharmaceutical company dedicated to enhancing patient access to cutting-edge therapies in international markets, has announced an expansion of its collaboration with Alnylam Pharmaceuticals), a frontrunner in RNAi therapeutics. This expanded partnership now covers Central and Eastern Europe and Israel, along with select markets in Latin America and the Asia-Pacific region, as well as other international territories.

“We are delighted to extend yet again our existing partnership with Medison, which will enable us to enhance our presence and bring the benefits of Alnylam's innovative RNAi therapeutics to patients in additional APAC and LATAM markets. Medison is at the forefront of the global trend of consolidating international markets under one alliance. Together, we'll provide faster access to more patients around the world,” stated Norton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam.

Medison, a pioneer in the multi-regional partnership space, has developed a distinctive and cohesive commercialization platform aimed at international markets, with a focus on treating rare and severe diseases. As the only partner committed exclusively to the most innovative therapies, Medison sets itself apart in the industry. The collaboration between Alnylam and Medison began in 2018 and has since broadened to encompass more regions and markets. This expansion ensures that Alnylam's commercial therapies—including ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran)—are accessible to patients across various international markets.

Meir Jakobsohn, Founder and Executive Chairman of Medison, said "The new category of the multi-regional partnerships that we have been creating in the past few years continues to get traction with the most innovative biotech companies. We are proud of our longstanding partnership with Alnylam and will continue to work together to bridge geographical gaps, ensuring that Alnylam's life-saving therapies reach patients in need."

"Our unified commercial platform enables biotech companies to transform numerous complex and fragmented markets and regions into a unified territory, and we are proudly leading the trend and the category," remarked Gil Gurfinkel, CEO of Medison.

He further added, “Our expanding partnership with Alnylam shows just how our one-of-a-kind unified commercial platform, with single alliance management across multiple markets and regions, is of great value to leading biotech companies. This partnership will make Alnylam's therapies available in additional international markets, offering newfound hope for patients suffering from rare diseases.”